

Supplementary material

Table S1: **Number of participants/missing data**


			Total TRD	Controls
Total number of ADD participants with baseline inflammatory and clinical data			143	31
	Metyrapone	Placebo	Total TRD	Controls
Total numbers after exclusions for inflammatory conditions ^a	63	66	129	28
Number after exclusion of non-adherent metyrapone patients ^b	40	66	106	-
Number of participants (excluding metyrapone non-adherent) with clinical and inflammatory outcome data ^c	40	57	97	-

^a included in baseline patient/control comparisons, and the mITT moderation and mediation analyses

^b included in per-protocol moderation and mediation analyses

^c included in analyses with missing data addressed using full information maximum likelihood

Figure S1

**Figure a-d:** Patients' and controls' baseline levels of

- a) IL-6
- b) TNF α
- c) CRP
- d) IL-10

Log transformed mean values of the cytokines assessed are presented. Error bars represent standard deviation (SD).
 CRP = C-reactive Protein; IL-6 = Interleukin 6; IL-10 = Interleukin 10; TNF- α = Tumour Necrosis Factor α .

Figure S2




Figure A / B: IL-6 associations with treatment group and clinical outcome, as examined in linear regression and mediation analysis

a) Pre-treatment IL-6 as a predictor of subsequent clinical outcome

b) Change in IL-6 during treatment and association with clinical outcome